Evaluation and comparison of microvessel density using the markers CD34 and CD105 in regenerative nodules, dysplastic nodules and hepatocellular carcinoma

详细信息    查看全文

• 作者：Vanderlei Segatelli (1)
  Ebe Christie de Oliveira (1)
  Ilka F. S. F. Boin (2)
  Elaine Cristina Ataide (3)
  Cecilia Amelia F. Escanhoela (4)
  
• 关键词：Microvessel density ; Angiogenesis ; Hepatocellular carcinoma ; Dysplastic nodules ; Regenerative nodules
• 刊名：Hepatology International
• 出版年：2014
• 出版时间：April 2014
• 年：2014
• 卷：8
• 期：2
• 页码：260-265
• 全文大小：706 KB
• 参考文献：1. Tsukuma H, Hiyama T, Tanaka S, Nakao M, Yabuuchi T, Kitamura, et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993;328(25):1797-801
  2. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007;132(7):2557-576
  3. Theise ND, Park YN, Curado MP, et al. Hepatocellular carcinoma. In: Bosman FT, Carneiro F, Hruban RH, Theise ND, editors. WHO Classification of Tumours of the Digestive System. Lyon: IARC Press; 2010. 205-16
  4. Theise ND, Park YN, Kogiro M. Dysplastic nodules and hepatocarcinogenesis. Clin Liver Dis 2002;6(2):497-12
  5. Villanueva A, Newell P, Chiang DY, Friedman SL, Llovet JM. Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis 2007;27(1):55-6
  6. Pang RW, Joh JW, Johnson PJ, Monden M, Pawlik TM, Poon RT. Biology of hepatocellular carcinoma. Ann Surg Oncol 2008;15(4):962-71
  7. Hytiroglou P. Morphological changes of early human hepatocarcinogenesis. Semin Liver Dis 2004;24(1):65-5
  8. Park YN, Yang CP, Fernandez GJ, Cubukcu O, Thung S, Theise ND. Neoangiogenesis and sinusoidal “capillarization-in dysplastic nodules of the liver. Am J Surg Pathol 1998;22(6):656-62
  9. Semela D, Dufour JF. Angiogenesis and hepatocellular carcinoma. J Hepatol 2004;41:864-80
  10. Deli G, Jin CH, Mu R, Yang S, Liang Y, Chen D, et al. Immunohistochemical assessment of angiogenesis in hepatocellular carcinoma and surrounding cirrhotic liver tissues. World J Gastroenterol 2005;11:960-63
  11. International Working Party. Terminology of nodular hepatocellular lesions. Hepatology 1995;22(3):983-93
  12. Hytiroglou P, Park YN, Krinsky G, Theise ND. Hepatic precancerous lesions and small hepatocellular carcinoma. Gastroenterol Clin N Am 2007;36:867-87
  13. International Consensus Group for Hepatocellular Neoplasia. Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia. Hepatology 2009;49(2):658-64
  14. Roncalli M, Borzio M, Di Tommaso L. Hepatocellular dysplastic?nodules. Ann Ital Chir 2008;79(2):81-9
  15. Sakamoto M, Effendi K, Masugi Y. Molecular diagnosis?of?multistage?hepatocarcinogenesis. Jpn J Clin Oncol 2010;40(9):891-96
  16. Shiraha H, Yamamoto K, Namba M. Human?hepatocyte?carcinogenesis?(review). Int J Oncol 2013;42(4):1133-138
  17. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285(21):1182-186
  18. Folkman J. Tumor angiogenesis. Adv Cancer Res 1985;43:175-03
  19. Folkman J, Shing Y. Angiogenesis. J Biol Chem 1992;267(16):10931-0934
  20. Frachon S, Gouysse G, Dumortier J, Couvelard A, Nejjari M, Mion F, et al. Endothelial cell marker expression in dysplastic lesions of the liver: an immunohistochemical study. J Hepatol 2001;34(6):850-57
  21. Di Carlo I, Fraggetta F, Lombardo R, Azzarello G, Vasquez E, Puleo S. CD34 expression in chronic and neoplastic liver diseases. Panminerva Med 2002;44(4):365-67
  22. Yang L, Lu W, Huang G, Wang W. Correlation between CD105 expression and postoperative recurrence and metastasis of hepatocellular carcinoma. BMC Cancer 2006;6:110
  23. Nakamura T. Changes in expression of bile canalicular CD10 and sinusoidal CD105 (endoglina) in peri-tumoral hepatic tissue. Tumori 2009;95(4):495-00
  24. Wang Y, Zhang XH, Guo P, Yan LN, He D. Tumor microvascular density detected by anti-CD105?and anti-CD34 in?hepatocellular carcinoma?patients and its predictive value of tumor recurrence after liver transplantation. Sichuan Da Xue Xue Bao Yi Xue Ban 2010;41(5):818-82
  25. Ho JW, Poon RT, Sun CK, Xue WC, Fan ST. Clinicopathological and prognostic implications of endoglin (CD105) expression in hepatocellular carcinoma and its adjacent non-tumorous liver. World J Gastroenterol 2005;11(2):176-81
  26. Yu D, Zhuang L, Sun X, Chen J, Yao Y, Meng K, et al. Particular distribution and?expression?pattern of endoglin (CD105) in the liver of patients with?hepatocellular carcinoma. BMC Cancer 2007;7:122
  27. Wang ZS, Wu LQ, Yi X, Geng C, Li YJ, Yao RY. Connexin-43 can delay early recurrence and metastasis in patients with hepatitis B-related?hepatocellular carcinoma?and low serum alpha-fetoprotein after radical hepatectomy. BMC Cancer 2013;13(1):306
  
• 作者单位：Vanderlei Segatelli (1)
  Ebe Christie de Oliveira (1)
  Ilka F. S. F. Boin (2)
  Elaine Cristina Ataide (3)
  Cecilia Amelia F. Escanhoela (4)
  
  1. Department of Pathology, Hospital Albert Einstein, Avenida Albert Einstein, 627, Morumbi, S?o Paulo, SP, 05652-900, Brazil
  2. Unit of Liver Transplantation, Faculty of Medical Science, UNICAMP, Campinas, SP, Brazil
  3. Faculty of Medical Science, UNICAMP, Campinas, SP, Brazil
  4. Department of Pathology, Faculty of Medical Science, UNICAMP, Campinas, SP, Brazil
  
• ISSN：1936-0541

文摘

Purpose The progression of hepatocellular carcinoma (HCC) is multifactorial and angiogenesis plays a fundamental role, mainly because HCC is a highly vascularized tumor. Methods In this study, we determined microvessel density (MVD) using the immunohistochemical markers, CD34 and CD105 (Endoglin), in 44 hepatectomy specimens, encompassing 44 malignant nodules (HCC), 44 regenerative nodules (RN), and 15 dysplastic nodules (DN). The evaluation included the determination of MVD in all nodules. For statistical analysis, a descriptive analysis was carried out using measurements of position and dispersion for continuous variables; ANOVA was used to compare between groups, considering p?<?0.05 as statistically significant. Results We observed a significant difference when comparing CD34 and CD105 immunoexpression in HCC, DN, and RN. CD105 was predominantly expressed in the peripheral regions in HCC, with mean MVD scores of 6.2?±?4.1 and 10.7?±?4.4 at the center and periphery of the nodules, respectively, with significant differences between groups (p?<?0.0001). CD34 had higher mean MVD scores than CD105 in HCC, with a more uniform positivity pattern. CD105 immunoexpression in DN exhibited a pattern similar to HCC. However, in RN, CD105 exhibited a higher MVD score in the central portion of the nodules. CD105 was expressed in a subset of newly formed microvessels in HCC and demonstrated an elevated mean MVD in cirrhotic or regenerative nodules. Conclusions MVD determined by CD34 and CD105 expression may be used as an additional parameter to distinguish benign from malignant liver nodules.